# FMT to Convert Response to Immunotherapy

> **NCT05251389** · PHASE1,PHASE2 · RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 24 (estimated)

## Conditions studied

- Melanoma Stage III
- Melanoma Stage IV

## Interventions

- **OTHER:** Fecal microbiota transplantation

## Key facts

- **NCT ID:** NCT05251389
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-31
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05251389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05251389, "FMT to Convert Response to Immunotherapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05251389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*